Cytokinetics
Cytokinetics reports $1.4 million in revenue from R & D collaborations in second quarter
Published in Cardiovascular Business Week, August 22nd, 2006
Net loss for the second quarter of 2006 was $13.3 million, or $0.37 per share. As of June 30, 2006, cash, cash equivalents, restricted cash and marketable securities totaled $100.0 million.
"The second quarter of 2006 was eventful for Cytokinetics as we announced promising data from our cardiovascular and oncology programs and extended our research collaboration with GlaxoSmithKline. In June, we shared positive top-line results from our Phase I clinical trial with CK-1827452, which we believe may prove to be...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
More Articles from Cardiovascular Business Week
- Biosite
Biosite notes 45% increase in sales of cardiovascular products - Biovail
Biovail and Athpharma terminate joint development agreement - Edwards Lifesciences
Edwards Lifesciences reports strong second quarter earnings - Endologix
Endologix reports continued significant growth during second quarter in U.S. product sales - Finance
Merit Medical reports record Q2 2006 revenues of $48.1 million, up 13.5% over Q2 2005 - Millennium Pharmaceuticals
Millennium Pharmaceuticals reports strong Q2 2006 results, progress in marketing Velcade - More from this issue of Cardiovascular Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
